Moderate-to-severe atopic dermatitis

Active Ingredient: Dupilumab

Indication for Dupilumab

Population group: only adolescents (12 years - 18 years old)

Dupilumab is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.

For this indication, competent medicine agencies globally authorize below treatments:

200-600 mg once every 2 weeks

Route of admnistration

Subcutaneous

Defined daily dose

200 - 600 mg

Dosage regimen

From 200 To 600 mg once every 14 day(s)

Loading dose

600 mg

Maintenance dose

300 mg

Detailed description

The recommended dose of dupilumab for adolescent patients 12 to 17 years of age is specified in the following table.

Dose of dupilumab for subcutaneous administration in adolescent patients 12 years to 17 years of age with atopic dermatitis:

Body Weight of PatientInitial DoseSubsequent Doses (every other week)
less than 60 kg400 mg (two 200 mg injections) 200 mg
60 kg or more600 mg (two 300 mg injections) 300 mg

Dupilumab can be used with or without topical corticosteroids. Topical calcineurin inhibitors may be used, but should be reserved for problem areas only, such as the face, neck, intertriginous and genital areas.

Consideration should be given to discontinuing treatment in patients who have shown no response after 16 weeks of treatment for atopic dermatitis. Some patients with initial partial response may subsequently improve with continued treatment beyond 16 weeks. If dupilumab treatment interruption becomes necessary, patients can still be successfully re-treated.

Missed dose

If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.

Dosage considerations

Dupilumab is administered by subcutaneous injection into the thigh or abdomen, except for the 5 cm around the navel.

Active ingredient

Dupilumab

Dupilumab is a recombinant human IgG4 monoclonal antibody that inhibits interleukin-4 and interleukin-13 signaling. Dupilumab inhibits IL-4 signaling via the Type I receptor (IL-4RĪ±/Ī³c), and both IL-4 and IL-13 signaling through the Type II receptor (IL-4RĪ±/IL-13RĪ±). IL-4 and IL-13 are major drivers of human type 2 inflammatory disease, such as atopic dermatitis, asthma, and CRSwNP. Blocking the IL-4/IL-13 pathway with dupilumab in patients decreases many of the mediators of type 2 inflammation.

Read more about Dupilumab

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.